HC Wainwright & Co. Maintains Buy on G1 Therapeutics, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White maintains a Buy rating on G1 Therapeutics (NASDAQ:GTHX) but lowers the price target from $9 to $3.
June 25, 2024 | 11:28 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
HC Wainwright & Co. analyst Edward White maintains a Buy rating on G1 Therapeutics but lowers the price target from $9 to $3.
The lowered price target from $9 to $3 indicates a significant reduction in the expected valuation of G1 Therapeutics, which is likely to negatively impact the stock price in the short term despite the maintained Buy rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100